Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MAP2K4 |
| Gene Name: | MAP2K4 |
| Protein Full Name: | Dual specificity mitogen-activated protein kinase |
| Alias: | C-Jun N- terminal kinase kinase 1; C-JUN N-terminal kinase kinase 1; EC 2.7.12.2; JNK activating kinase 1; JNK kinase 1; JNKK; JNKK 1; JNKK1; Kinase SEK1; MAP kinase kinase 4; MAPK,ERK kinase 4; MAPK/ERK kinase 4; MAPKK 4; MEK4; Mitogen-activated protein kinase kinase 4; MKK4; MP2K4; PRKMK4; SAPK,ERK kinase 1; SAPK/ERK kinase 1; SEK1; SERK1 |
| Mass (Da): | 44288 |
| Number AA: | 399 |
| UniProt ID: | P45985 |
| Locus ID: | 6416 |
| COSMIC ID: | MAP2K4 |
| Gene location on chromosome: | 17p12 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 23214 |
| Percent of cancer specimens with mutations: | 0.98 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with many point mutations and 3 deletions, but no insertions or complex mutations across the entire protein. |
| Normal role description: | MAP2K4 is a protein-serine/threonine/tyrosine kinase. Involved in MAPK signalling in response to stressors or mitogens. It signals through JNK1/JNK2, ERK1/ERK2, p38 and more. It has arole in maintaining peripheral lymphoid homeostasis and apoptosis. Mutations and deletions of this genes leads to dysregulated JNK signalling and promotes oncogenesis. |